Historique
Périodique
Pathways into ecstasy use: The role of prior cannabis use and ecstasy availability
(Voies d'entrée dans l'usage d'ecstasy : rôle d'un usage préalable de cannabis et d'un accès plus facile à l'ecstasy)
Auteur(s) :
ZIMMERMANN, P. ;
WITTCHEN, H. U. ;
WASAK, F. ;
NOCON, A. ;
HÖFLER, M. ;
LIEB, R.
Année :
2005
Page(s) :
331-341
Langue(s) :
Anglais
Refs biblio. :
71
Domaine :
Drogues illicites / Illicit drugs
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus mots-clés
MDMA-ECSTASY
;
CANNABIS
;
INITIATION
;
FACTEUR DE RISQUE
;
CONSOMMATION
;
INCIDENCE
Thésaurus géographique
ALLEMAGNE
Note générale :
Drug and Alcohol Dependence, 2005, 79, (3), 331-341
Note de contenu :
fig. ; tabl.
Résumé :
ENGLISH :
Aim : To explore the role of cannabis use for the availability of ecstasy as a potential pathway to subsequent first ecstasy use. Methods: Baseline and 4-year follow-up data from a prospective-longitudinal community study of originally 3021 adolescents and young adults aged 14-24 years at baseline were assessed using the standardized M-CIDI and DSM-IV criteria. Results : Baseline cannabis users reported at follow-up more frequent access to ecstasy than cannabis non-users. Higher cannabis use frequencies were associated with increased ecstasy availability reports. Logistic regression analyses revealed that cannabis use and availability of ecstasy at baseline are predictors for incident ecstasy use during the follow-up period. Testing simultaneously the impact of prior cannabis use and ecstasy availability including potential confounders, the association with cannabis use and later ecstasy use was confirmed (OR = 6,3 ; 95% CI = 3,6 - 10,9). However, the association with ecstasy availability was no longer significant (OR = 1,2 ; 95% CI = 0,3 - 3,9). Conclusions : Results suggest that cannabis use is a powerful risk factor for subsequent first onset of ecstasy use and this relation cannot be sufficiently explained by availability of ecstasy in the observation period. (Review's abstract.)
Affiliation :
Max Planck Institute of Psychiatry, Clinical Psychology and Epidemiology, Kraepelinstrasse 2, 80804 Munich
Allemagne. Germany.
Allemagne. Germany.